Revenio Group is a Finnish medtech company operating within development and manufacturing of diagnostic screening devices for eye diseases. Revenio's business operations include patient-driven screening, diagnostics and follow-up monitoring of ophthalmologic diseases. The company focus on developing efficient and easily adopted methods for the early-stage detection of globally prevailing eye diseases, including glaucoma, diabetic retinopathy, macular degeneration and cataract as well as the monitoring of these during the treatment process. In addition, Revenio also, albeit at an early stage of commercialisation, develops systems that support the diagnosis of skin cancer and asthma in small children and planning their treatment.
Revenio is headquartered in Helsinki, Finland, and has approx. 130 employees. In 2020, the company’s net sales totaled EUR 61 million with an adjusted EBITDA margin of 36%. Revenio Group is listed on Nasdaq OMX Helsinki.
William Demant Invest started investing in Revenio in 2018 and is today the largest shareholder with approx. 12% ownership.